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ABSTRACT: Cardiac arrest is a condition in which the heart 
mechanical functioning is compromised and usually it is due 
an electrical dysfunction of the cardiac cells and this can result 
in disorganization of cardiac rhythm and even heart failure, a 
situation of medical emergency in which seconds can make the 
difference between life and death. In cardiac arrest, it’s necessary 
to perform cardiopulmonary resuscitation (CPR) maneuver and, 
if there are shockable rhythms (such as ventricular fibrillation 
and pulseless ventricular tachycardia), defibrillation should 
be administered on the patient. Even if the cardiac rhythm is 
reestablished, the condition is still serious due to the risk of 
recurrent electrical alteration of the heart. With the intent of 
avoiding a new rhythmic alteration of the heart, it’s ministered 
antiarrhythmic drugs, such as amiodarone or lidocaine. Even 
though the use of one of these drugs is recommended, there are no 
consensuses about which one has higher survival rate of patients 
or which has the highest rate of return of spontaneous circulation. 
Thus, this systematic review aims to clarify which one of these 
two drugs is more efficient at preventing new electrical alterations 
of patients post cardiorespiratory arrest.
Keywords: Cardiac arrest; Antiarrhythmic drugs; Amiodarone; 
Lidocaine; Patient survival rate.
RESUMO: A parada cardíaca é uma condição em que o 
funcionamento mecânico do coração é comprometido e usualmente 
é devida a uma disfunção elétrica das células cardíacas, que pode 
resultar na desorganização do ritmo cardíaco, até numa falência 
cardíaca, uma situação de emergência médica em que segundos 
podem fazer a diferença entre a vida e a morte. Na parada 
cardíaca, é necessário que se realizem manobras de reanimação 
cardiopulmonar (RCP) e, caso haja presença de ritmo chocável 
(como a fibrilação ventricular e taquicardia ventricular sem pulso), 
se administre a desfibrilação no paciente. Mesmo que o ritmo 
cardíaco seja restabelecido, a condição ainda é grave devido ao 
risco de retorno da alteração elétrica do coração. Com a intenção 
de evitar novas alterações rítmicas do coração, são administradas 
drogas antiarrítmicas, como amiodarona e lidocaína. Embora seja 
recomendado o uso de um desses fármacos, não há consenso 
sobre qual deles tem maior sobrevida de pacientes, ou qual tem 
maior taxa de retorno de circulação espontânea. Sendo assim, 
essa revisão sistemática busca elucidar qual dessas duas drogas é 
mais eficiente para evitar novas alterações elétricas em pacientes 
pós-parada cardiorrespiratória.
Descritores: Parada cardíaca; Drogas antiarrítmicas; Amiodarona; 
Lidocaína; Sobrevida de pacientes.
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INTRODUCTION
Improving the outcome of out-of-hospital cardiac arrest (OHCA) is still a major healthcare 
challenge, due to the high mortality rates associated to 
this condition. Annually, approximately 420 000 cases 
were reported In United States and 275 000 in Europe1. 
More important, the fatality rate is generally more than 
95 percent2. 
Sudden cardiac arrest (SCA) is defined as a natural 
and unexpected collapse of presumed cardiac etiology3. 
There are several conditions that may lead to the heart to 
suddenly lose its pumping capacity. In spite of the cause, 
if not treated immediately and properly, death may result 
in a few minutes4.
Ventricular fibrillation (VF) and pulseless ventricular 
tachycardia (pVT) are the most common cause of cardiac 
arrest, being responsible for approximately 85% of sudden 
cardiac deaths5. Both conditions are treated primarily 
by cardiopulmonary resuscitation (CPR)6 and electrical 
defibrillation, and therefore, have better outcomes when 
compared to other causes of cardiac arrest that do not 
respond to this kind of procedure (for example, asystole)7.
Patients who return to spontaneous circulation 
(ROSC) after CPR and defibrillation, however, may 
present recurrence of these malignant arrhythmias. Hence, 
antiarrhythmic drugs, such as amiodarone or lidocaine, 
are frequently administered during and immediately after 
VF/pVT to reverse these dysrhythmias and prevent their 
relapse8.
Amiodarone is a class III antiarrhythmic drug, 
according to the Vaughan-Williams Classification. Its 
properties includes inhibiting potassium, sodium and 
calcium channels. It also has anti-adrenergic effects 
by blocking the alfa and beta receptors. Amiodarone is 
indicated in patients with VF/pVT, after unsuccessful 
defibrillation9,10. Lidocaine is a class I antiarrhythmic drug, 
with sodium channel blockade. It has been used in VF 
patients who are refractory to defibrillation11,12.
In 2015, the International Liaison Committee 
on Resuscitation (ILCOR) issued a guideline that 
recommended preferentially the use of amiodarone as the 
first choice of treatment for adult patients with VF/pVT2. 
However, studies point that both lidocaine and amiodarone 
are equivalent at preventing the refractory VF/pVT2,13.
Since no agreement is observed in recent medical 
literature, and new studies addressing this issue have been 
recently published, our goal in this systematic review was to 
evaluate different studies comparing both of these drugs to 
find out which one of them can be more efficient clinically. 
METHODS
Data sources and search strategy
For this systematic review, three databases were 
researched: SciELO, LILACS and Pubmed. In our access 
in November, 2018, no article with the desirable terms 
were found in SCielo or LILACS, therefore, only PubMEd 
results were reported. 
Our search was structured by the following terms: 
“amiodarone [MeSH Terms] AND lidocaine[MeSH 
Terms] AND (resuscitation[MeSH Terms] OR cardiac 
arrest[MeSH Terms] OR cpr[MeSH Terms])”. Filters were 
applied for language (English) and species (human).
Eligibility criteria and study selection
Inclusion criteria were pre-specified according to 
the PICOS approach (Table 1). We excluded studies about 
pediatric cardiac arrest, reviews, editorials, comments and 
letters to editor (Figure 1).
 
Table 1. PICOS approach for selecting studies in the systematic search
Population Adult patients in cardiac arrest with recurrent (restarting after successful termination) VF/pVT, including in- and out-of-hospital setting
Intervention Administration of amiodarone
Comparison Lidocaine, placebo, combination of amiodarone and lidocaine, no drugs administered
Outcomes
Survival to admission to the hospital, survival to hospital discharge, favorable neurologic function at discharge, 
survival at 24 hrs/1-year post cardiac arrest
Study design Randomized clinical trials and retrospective studies
*VF: ventricular fibrillation/ pVT: pulseless ventricular tachycardia 
48
Rev Med (São Paulo). 2020 Jan-Feb;99(1):46-55.
Figure 1. Flow diagram of included studies
Outcomes of interest
Endpoints of interest included survival to hospital 
admission, survival to hospital discharge, favorable 
neurologic status (modified Rankin score ≤3) at 
discharge, survival at 24 hrs/1-year post cardiac arrest, 
and adverse events.
RESULTS
The search identified 46 potentially relevant studies. 
As shown in the flow diagram (Figure 1), after applying 
filters and eliminating articles that did not meet the eligible 
criteria, six papers were selected for inclusion in the 
review: three randomized controlled trials (RCTs) and three 
retrospective medical record reviews. Initially, clinical trials 
and retrospective studies were analyzed separately. Table 
2 and 3 present basic information of the included articles. 
Table 2. Basic information of included clinical trials
Clinical Trial Year Author Journal
Amiodarone as Compared with Lidocaine for Shock-Resistant 
Ventricular Fibrillation2 2002 Dorian et al. N Engl J Med
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest13 2016 Kudenchuk et al. N Engl J Med
Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-
Hospital Cardiac Arrest: The Amiodarone, Lidocaine or Placebo Study 
(ALPS)14
2017 Kudenchuk et al. AHA Circulation
* N Engl J Med: The New England Journal of Medicine/ AHA: American Heart Association
Table 3. Basic information of included retrospective studies  
Retrospective Study Year Author Journal
Comparing intravenous amiodarone or lidocaine, or both, outcomes 
for inpatients with pulseless ventricular arrhythmias15 2006 Rea et al. Crit Care Med
Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac 
Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a 
Nationwide Database Study7
2016 Tagami et al. Cardiovasc Drugs Ther
Acute hospital administration of amiodarone and/or lidocaine in 
shockable patients presenting with out-of-hospital cardiac arrest: a 
nationwide cohort study16
2016 Huang et al. Int J Cardiol
Characteristics of included studies
a) Methods
All three clinical trials selected for the review were 
randomized and double-blind. The duration of the study 
published in 20025 was 5 years and 5 months and both 
studies conducted by Kudenchuk et al.13,14 have the same 
duration (3 years, 5 months and 18 days) and setting. 
The research led by Kudenchuk et al.13,14 compared 
amiodarone, lidocaine and saline placebo after successful 
ROSC. Meanwhile, Dorian et al.2 used a different 
experimental design; each kit given to paramedics 
contained either active amiodarone and lidocaine placebo 
or active lidocaine and amiodarone placebo. There was no 
saline placebo having its effect compared to antiarrhythmic 
drugs (Table 4).
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Table 4. Clinical trials: study characteristics
Clinical Trial Allocation Blinding Comparison between Duration Setting
Dorian et al., 2002 Randomized Double-blind Amiodarone and lidocaine
November 
1995 - April 
2001
Toronto EMS system, 
that follows treatment 
protocols in accordance 
with the AHA guidelines 
for ALCS
Kudenchuk et al., 2016 Randomized Double-blind Amiodarone, lidocaine and placebo
May 7, 2012 
- October 25, 
2015
55 EMS agencies across 
10 North American sites 
participating in the ROC
Kudenchuk et al., 2017 Randomized Double-blind Amiodarone, lidocaine and placebo
May 7, 2012 
- October 25, 
2015
55 EMS agencies across 
10 North American sites 
participating in the ROC
*EMS: emergency medical services/ ROC: Resuscitation Outcomes Consortium/ AHA: American Heart Association/ ACLS: advanced cardiac life support
We analyzed three retrospective studies, one 
from a multicenter study conducted in the USA15, one 
from the Japanese Diagnosis Procedure Combination 
inpatient database7 and one from the Taiwan’s National 
Health Insurance Research Database (NHIRD)16. August 
1, 2000, the start date for data collection of Rea et al.15 
study, is the date of the publication of the 2000 guidelines 
recommending amiodarone over lidocaine for VF/ pVT. 
The retrospective studies compared routes of 
drug administration, drug dose and outcomes in patients 
receiving amiodarone or lidocaine or both or neither during 
the period of analysis (Table 5).
Table 5. Retrospective studies: article type, comparison and time interval covered by the studies
Retrospective study Article type Comparison between Patients included if admitted between
Rea et al., 2006
Retrospective medical record review: 
comparative multicenter study (3 medical 
centers in the USA)
Amiodarone, lidocaine and 
combination of amiodarone and 
lidocaine
August 1, 2000 and 
August 1, 2002
Tagami et al., 2016
Nationwide database study: medical 
records from Japanese Diagnosis 
Procedure Combination inpatient 
database
Amiodarone and lidocaine July 2007 and March 2013
Huang et al., 2016
Nationwide cohort study: medical records 
from Taiwan National Health Insurance 
Research Database (NHIRD)
Both (amiodarone and 
lidocaine), amiodarone 
(amiodarone only), lidocaine 
(lidocaine only), and neither
January 2004 and 
December 2011.
b) Participants
Table 6 and 7 summarizes the characteristics of 
participants of chosen clinical trials and retrospective 
studies, respectively. In all included studies2,7,13,14,16, patients 
were eligible if they were adults with non-traumatic 
OHCA, except in the study of Rea et al.15, that compared 
survival rates of in-hospital cardiac arrest treated with 
amiodarone or lidocaine or a combination of both. In the 
studies of Kudenchuk et al.13,14, patients presenting with 
initial shock-refractory VF/VT were reported and analyzed 
in the research published in 201613. The study published 
in 2017 also by Kudenchuk et al.14, was an analysis in a 
separate cohort that initially had nonshockable OHCA and 
subsequently developed shock-refractory VF/VT. 
The mean age of enrolled patients was over 60 years, 
and most patients were male. 
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Table 6. Clinical trials: patients
Clinical Trial Eligible patients N Mean [±SD] age Sex
Dorian et al., 2002
Non-traumatic OHCA VF resistant to 3 
shocks, intravenous epinephrine, and a 
further shock; or recurrent VF after initially 
successful defibrillation
347 67±14 years Male sex – 78%
Kudenchuk et al., 2016
Non-traumatic OHCA, shock-refractory VF 
or pVT after at least one shock, and with 
vascular access
3026
63.7±14.0 years 
(amiodarone)
63.0±14.7 years 
(lidocaine)
62.7±14.6 years (placebo)
Male sex – 
80%
Kudenchuk et al., 2017
Nonshockable-turned-shockable non-
traumatic OHCA: patients with initially 
nonshockable arrest rhythm that subsequently 
developed VF/VT refractory to ≥1 shock(s)
1063 64.5±16.5 years Male sex – 70%
* OHCA: out-of-hospital cardiac arrest/ VF: ventricular fibrillation/ pVT: pulseless ventricular tachycardia/ Plus–minus values are means ±SD 
(standard deviation)
Table 7. Retrospective studies: patients
Retrospective 
Study Eligible patients N Mean [±SD] age Sex
Rea et al., 2006 IHCA secondary to VF/ pVT 194
62±14.0 years (amiodarone)
64.0±17 years (lidocaine)
65±12 years (combination)
Male sex – 72%
Tagami et al., 2016 Cardiogenic OHCA and refractory VF/ pVT 3951
68.4±15.1 years (amiodarone)
64.4±17.5 years (lidocaine)
Male sex – 75%
Huang et al., 2016
Non-traumatic OHCA undergoing 
DC shock and cardiopulmonary 
resuscitation during short emergency 
room stay (<6h)
27463
62.01 ± 15.76 years (both)
64.75 ± 16.18 years (amiodarone)
66.83 ± 16.28 years (lidocaine)
67.10 ± 17.19 years (neither)
Male sex – 67%
* IHCA: in-hospital cardiac arrest/ OHCA: out-of-hospital cardiac arrest/ VF: ventricular fibrillation/ pVT: pulseless ventricular tachycardia/ DC: 
direct-current/ Plus–minus values are means ±SD (standard deviation)
c) Intervention
In order to better compare the intervention among 
the studies, we listed the CPR procedures performed in 
patients included in each study. Table 8 and 10 summarize 
event characteristics and CPR maneuvers in patients 
analyzed, respectively, by clinical trials and retrospective 
studies. Table 9 and 11 present information about routes 
of drug administration and drug dose, in clinical trials and 
retrospective studies.
In clinical trials2,13,14, amiodarone and lidocaine 
groups did not differ significantly in treatment or procedure, 
except for the infused experimental drug. 
Dorian et al.2 also evaluated the effect of time between 
the dispatch of the paramedics and the administration of 
the study drug on the proportion of patients with improved 
outcome: among patients for whom the length of time was 
equal or less than the median time (24 minutes), a higher 
proportion of patients survived to hospital admission was 
detected. 
Drug doses administered were the same in both 
studies by Kudenchuk et al.13,14 (300 mg of amiodarone and 
120 mg of lidocaine, as initial dose, if the estimated body 
weight was >45.4 kg) and similar doses were used in the 
other clinical trial evaluated..
In retrospective studies7,15,16, there was a lack of 
information about the cardiac arrest event and the treatment 
they received before the administration of antiarrhythmic 
drugs. 
In Rea et al.15, the standard deviation values for 
antiarrhythmic drugs doses are high, except for the second 
dose of amiodarone, which is zero (150±0 mg; since one 
syringe of amiodarone contains 150 mg, for practical 
reasons, more commonly the patient in an emergent 
situation may be given 150 mg. Difficulties in preparing 
and administering amiodarone have been reported during 
cardiac arrest). Tagami et al.7 did not provide drug doses.
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Table 8. Clinical trials: cardiac arrest and resuscitation
Clinical Trial Time from dispatch to arrival of paramedics
Time from dispatch to  
first dose of trial drug
Compression/Defibrillation/Ventilation
Dorian et al., 2002 7±3 minutes 25±8 minutes
CPR by bystander (27%), procedures 
performed by paramedics (shock and 
intubation)
Kudenchuk et al., 2016
5.8±2.6 min (amiodarone)
5.6±2.4 min (lidocaine)
5.8±2.6 min (placebo)
19.3±7.4 minutes
CPR by bystander (56%), PAD shock by 
bystander (5,6%), procedures performed by 
paramedics (advanced airway management, 
shocks, compressions)
Kudenchuk et al., 2017 6.1±2.8 minutes 26.9±8.9 minutes
CPR by bystander (46%), procedures 
performed by paramedics (advanced airway 
management, shocks, compressions)
* CPR: cardiopulmonary resuscitation/ PAD: public access defibrillator/ Plus–minus values are means ±SD (standard deviation)
Table 9. Clinical trials: antiarrhythmic drugs
Clinical Trial Amiodarone: routes of drug administration and drug dose
Lidocaine: routes of drug administration 
and drug dose Placebo
Dorian et al., 2002
- Intravenous 
- 5 mg per kilogram of estimated body weight
- If VF persisted after a further shock, second 
dose was administered (2.5 mg per kg).
- Intravenous 
- 1.5 mg per kilogram at a concentration 
of 10 mg per mL - If VF persisted 
after a further shock, second dose was 
administered (1.5 mg per kg).
-
Kudenchuk et al., 
2016
- Intravenous or intraosseous
- Initial dose: 2 syringes (1 syringe if the 
estimated body weight was
<45.4 kg). Each syringe contained 150 mg of 
amiodarone.
- If VF persisted after a further shock, 
a supplemental dose (one syringe) was 
administered.
- Intravenous or intraosseous
- Initial dose: 2 syringes (1 syringe if the 
estimated body weight was <45.4 kg). Each 
syringe contained 60 mg of lidocaine.
- If VF persisted after a further shock, 
a supplemental dose (one syringe) was 
administered.
Saline 
placebo
Kudenchuk et al., 
2017
- Intravenous or intraosseous
- Initial dose: 2 syringes (1 syringe if the 
estimated body weight was
<45 kg). Each syringe contained 150 mg of 
amiodarone.
- If VF persisted after a further shock, 
a supplemental dose (one syringe) was 
administered.
-  Intravenous or intraosseous
- Initial dose: 2 syringes (1 syringe if the 
estimated body weight was <45 kg). Each 
syringe contained 60 mg of lidocaine.
- If VF persisted after a further shock, 
a supplemental dose (one syringe) was 
administered.
Saline 
placebo
*VF: ventricular fibrillation
Table 10. Retrospective studies: cardiac arrest and resuscitation 
Retrospective Study Time to initiation of CPR Time from dispatch to first dose of trial drug
Compression/Defibrillation/ 
Ventilation
Rea et al., 2006
1±2 min (amiodarone)
2±4 min (lidocaine)
22s±1 min (combination)
14±9 min (amiodarone)
6±5 min (lidocaine)
9±8 min (combination)
ACLS interventions at time of event:
-Intubation/ mechanical ventilation: 
50%
-Defibrillator: 1.5%
Tagami et al., 2016 Not available in the article Not available in the article EMS resuscitation procedures follow the Japanese guidelines for CPR
Huang et al., 2016 Not available in the article Not available in the article
Rate of bystander CPR was 31.4% in 
Taiwan/ Compressions, DC shocks, 
tracheal intubation
* CPR: cardiopulmonary resuscitation/ ACLS: advanced cardiovascular life support/ EMS: emergency medical services/ DC: direct-current/ Plus–
minus values are means ±SD (standard deviation)
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Table 11. Retrospective studies: antiarrhythmic drugs
Retrospective Study Amiodarone: routes of drug administration and drug dose
Lidocaine: routes of drug 
administration and drug dose
Combination of 
amiodarone and 
lidocaine
Rea et al, 2006
- Intravenous 
- First dose: 190±68.9 mg
- Second dose if VF persisted after 
a further shock: 150±0 mg
- Intravenous 
- First dose: 96.2±22 mg
- Second dose if VF persisted after a 
further shock: 78.7±31.8 mg
- Intravenous
Tagami et al, 2016
- Intravenous
- Drug dose: not available in the 
article
- Intravenous
- Drug dose: not available in the article -
Huang et al, 2016
- Intravenous
- First dose: 300 mg
- Second dose if VF persisted after 
a further shock: 150 mg
- Intravenous
- First dose: 1.0-1.5 mg per kilogram
- Second dose if VF persisted after a 
further shock: 0.5-0.75 mg per kg
- Intravenous
*VF: ventricular fibrillation/ Plus–minus values are means ±SD (standard deviation)
d) Outcomes 
Survival to hospital discharge was assessed in all 
studies2,7,13-16 either as a primary or secondary outcome 
depending on the study. 
The studies by Kudenchuk et al.13,14 included 
favorable neurologic function at discharge as a secondary 
endpoint. It was defined as a score on the modified Rankin 
scale (ranging from 0, no symptoms, to 6, death) of 3 or 
less, indicating the ability to conduct activities of daily 
living independently or with minimal assistance.
Adverse drug-related effects were analyzed by 
Dorian et al.2 and Kudenchuck et al.14. In Dorian et al.2, 
adverse events were defined as the need to administer 
atropine (treatment for bradycardia) or dopamine (pressor 
treatment) after administration of the study drug. In the 
latest trial by Kudenchuk et al.14, these effects were defined 
as those previously reported with these medications that 
occurred within 24 hours of their administration, including 
anaphylaxis, thrombophlebitis requiring treatment, clinical 
seizures, and bradycardia requiring temporary cardiac 
pacing.
In Huang et al.16, patients were followed for 1 year 
after the day of event or until loss to follow-up or death.
Table 12. Clinical trials: outcomes
Clinical Trial Outcome
Dorian et al., 2002 1. Survival to admission to the hospital ICU2. Survival to hospital discharge and adverse events
Kudenchuk et al., 2016 1. Survival to hospital discharge2. Favorable neurologic function at discharge
Kudenchuk et al., 2017 1. Survival to hospital discharge2. Favorable neurologic function at discharge and adverse events
* ICU: intensive care unit
Table 13. Retrospective studies: outcomes
Retrospective Study Outcome
Rea et al., 2006 1. Survival at 24 hrs post–cardiac arrest 2. Survival to hospital discharge
Tagami et al., 2016 1. Survival to hospital discharge
Huang et al., 2016 1. Survival at 1-year post–cardiac arrest
2. Survival to admission to the hospital ICU and survival to hospital discharge 
* ICU: intensive care unit
Results of Individual Studies
The results of included clinical trials are summarized 
in Table 12. Table 13 contains the results of retrospectives 
studies.
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Table 14. Clinical trials: results
Clinical Trial Primary outcome Secondary outcome
Dorian et al., 2002
1. Survival to admission to the hospital 
ICU =Amiodarone (180 patients total): 
41 (22.8%)
Lidocaine (167 patients total): 20 (12%)
2a. Survival to hospital discharge 
= 21% of patients who survived to hospital admission after 
receiving amiodarone and 25% of patients who survived 
to hospital admission after receiving lidocaine survived to 
hospital discharge
2b. Adverse events (need to administer atropine or dopamine 
after administration of the study drug)
= 24% and 23% of patients treated, respectively, with 
amiodarone and lidocaine needed treatment of bradycardia 
with atropine, and 7% and 4% of patients treated, respectively, 
with amiodarone and lidocaine needed pressor treatment with 
dopamine
Kudenchuk et al., 
2016
1. Survival to hospital discharge
= Amiodarone (974 total patients): 237 
(24.4%)
Lidocaine (993 total patients): 233 (23.7%)
Placebo (1059 total patients): 222 (21%)
2. Favorable neurologic function at discharge (modified Rankin 
score ≤3)
= Amiodarone: 18.8%
Lidocaine: 17.5%
Placebo: 16.6%
Kudenchuk et al., 
2017
1. Survival to hospital discharge
= Amiodarone (389 total patients): 16 
(4.1%)
Lidocaine (358 total patients): 11 (3.1%)
Placebo (316 total patients): 6 (1.9%)
2. Favorable neurologic function at discharge (modified Rankin 
score ≤3)
= Amiodarone: 2.1%
Lidocaine: 1.7%,
Placebo: 1%
* ICU: intensive care unit
Table 15. Retrospective studies: results
Retrospective 
Study Primary outcome Secondary outcome
Rea et al., 2006
1. Survival at 24 hrs post–cardiac arrest
= Both (only 34 patients out of 41 were available): 17 (50%)
Amiodarone (only 62 out of 74 were available): 34 (55%)
Lidocaine (only 68 out of 79 were available): 43 (63%)
2. Survival to hospital discharge
= Both (41 patients): 42%
Amiodarone (74): 39%
Lidocaine (79): 45%
Tagami et al., 
2016
1. Survival to hospital discharge
= Amiodarone (1743 total patients): 281 (16.1%)
Lidocaine (2208 total patients): 389 (17.6%)
-
Huang et al., 
2016
1. Survival at 1-year post–cardiac arrest
= Both (1487 total patients): 165 (11.10%)
Amiodarone (6459 total patients): 534 (8.27%)
Lidocaine (1077 total patients): 77 (7.15%)
Neither (18440 total patients): 602 (3.26%)
2a. Survival to admission to the hospital ICU 
= Both: 34.10%
Amiodarone: 27.17%
Lidocaine: 25.53%
Neither: 15.48%
2b.Survival to hospital discharge
= Both: 12.25%
Amiodarone: 9.54%
Lidocaine: 8.36%
Neither: 3.31%
Table 16 - Adjusted analysis on survival to hospital discharge
Dorian et al., 2002 Kudenchuk et al., 2016 Kudenchuk et al., 2017
1. Amiodarone vs. Placebo Not available in the article 3,2% (difference in survival) 2,5% (difference in survival)
-CI (95%) (-0.4 to 7.0) (-0.2 to 5.1)
-P value 0,08 0,07
2. Lidocaine vs. Placebo Not available in the article 2,6% (difference in survival) 1,1% (difference in survival)
-CI (95%) (-1.0 to 6.3) (-1.3 to 3.4)
-P value 0,19 0,28
3. Amiodarone vs. 
Lidocaine
2,49 (Odds ratio for survival 
between drugs) 0,7% (difference in survival) Not available in the article
-CI (95%) (-1.0 to 4.85) (-3.2 to 4.7)
-P value 0,007 0,7
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DISCUSSION
In this systematic review, direct and indirect 
evidence from three RCTs and three retrospective studies 
were analyzed to compare the effectiveness of amiodarone 
and lidocaine administered to reverse VF/pVT and prevent 
their recurrence in adults with non-traumatic cardiac arrest. 
Only one article affirmed the superiority of one 
drug over another in its outcome: Dorian et al.2 stated that 
amiodarone leads to substantially higher rates of survival to 
hospital admission, as compared with lidocaine. Huang et 
al.16 also evaluated the survival at hospital admission, and 
concluded that both medication did not differ significantly, 
although survival rates were improved with association of 
using drugs, as opposed to non-treatment.
Regarding survival at a hospital discharge: the 
studies suggest that there is no significant difference in the 
rate of survival between amiodarone and lidocaine2,7,13-16. 
In addition, research comparing antiarrhythmic drugs 
with placebo shows that neither amiodarone nor lidocaine 
resulted in a significantly higher rate of survival than the 
rate of placebo13,14. However, when comparing drugs with 
non-treatment, survival rates were higher in patients given 
medications16.
Limitations
This systematic review has several limitations. 
The RCTs and the retrospective studies are not directly 
comparable: since retrospective studies consist of analyzing 
outcomes that have already occurred from events that were 
not controlled, the quality tends to be lower than that of 
randomized double-blind clinical trials. High standard 
deviation values for antiarrhythmic drugs doses in Rea 
et al.15 show that there is no homogeneity in the doses 
administered, creating a variability inside the group of 
patients given amiodarone and inside the group given 
lidocaine. Even though the study acknowledges that despite 
existing recommended doses of Amiodarone or Lidocaine 
based on guidelines, not all of the patients received the 
suggested dosage. In contrast, two retrospective studies - 
Tagami et al.7 and Huang et al.16 - deal with a very large 
number of patients, which contribute to increase the quality 
of the studies, even though there are some information in 
this studies such as the time until drug administration or 
the dosage of drugs administered to patients that are not 
presented.
There are also differences in the emergency 
medical systems of the countries in which the studies 
were conducted: the included studies were performed in 
various countries, such as Canada2, North America13,14,15, 
Japan7 and Taiwan16. In the study conducted in North 
America13,14 patients were randomized at the scene by 
paramedics. Meanwhile, in Japan7, drugs were provided 
only after hospital arrival because paramedics are not 
allowed to administer any antiarrhythmic drugs (neither 
amiodarone nor lidocaine) in pre-hospital settings. This 
could be responsible for differences of time from cardiac 
arrest to first administration of the antiarrhythmic drug 
between the studies7.
Huang et al.16 doesn’t present how much time 
the patient was having a cardiac arrest before the arrival 
of paramedics and time until the administration of any 
drug. The article cites that amiodarone or lidocaine was 
administered within 20 minutes after the start of the clinical 
emergency. Moreover, there were no justifications on why 
the use of amiodarone simultaneously of lidocaine during 
the episodes of cardiac arrest
Rea et al.15 retrospective study points that the mean 
of time until the first administration of Lidocaine was 
of 6 minutes, while the mean of Amiodarone was of 14 
minutes and the mean of both drugs simultaneously was 
of 9 minutes. However, differently from the other articles 
this prospective study was realized within three academic 
medical centers in the United States, and the patients were 
already hospitalized and thus there was no significant time 
of cardiac arrest without medical assistance.
 
CONCLUSION
The data presented on the articles analyzed point 
to an inconclusive result. The only article to present a 
direct difference between both drugs is Dorian et al.2 which 
states a better overall survival rate of patients that received 
amiodarone. However, all of the other articles7,13-16 points 
to a non-existent difference between both drugs in overall 
survival rate of patients.
It’s possible that the different countries, communities, 
time of cardiac arrest and other variables influenced the 
outcome of all the articles, including the one by Dorian 
et al.2 and thus it’s recommended the design of new RTCs 
similarly to Kudenchuk et al.13,14 studies with the intent of 
reducing the number of variables that may influence or 
prevent the conclusion of which one of the drugs has higher 
patient survival rate.
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